Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 15/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279267 | 0.85 | KCNH2 (0.65) | KCNH2STK17BSTK17ABRD4 | |
| SCHEMBL17279268 | 0.83 | BRD4 (0.46) | STK17BSTK17ABRD4 | |
| SCHEMBL18905091 | 0.80 | KCNH2 (0.67) | KCNH2BRD4 | |
| SCHEMBL15822306 | 0.71 | KCNH2 (0.75) | KCNH2 | |
| SCHEMBL30897110 | 0.68 | STK17B (0.53) | STK17BSTK17ABRD4 | |
| SCHEMBL7972272 | 0.67 | BRD4 (0.43) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL17154889 | 0.66 | STK17B (0.56) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL31436060 | 0.65 | STK17B (0.58) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL7967420 | 0.64 | BRD4 (0.46) | STK17BSTK17ABRD4ADORA3ADORA2A | |
| SCHEMBL16024081 | 0.64 | CA1 (0.49) | STK17BSTK17ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174013-B2 | Benzimidazole derivatives as kinase inhibitors | SELVITA S.A. (PL) | 2019-01-08 | — | — | US | disclosed |
| US-10174013-B2 | Benzimidazole derivatives as kinase inhibitors | SELVITA S.A. (PL) | 2019-01-08 | — | — | US | disclosed |
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2017-06-01 | — | — | US | disclosed |
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2017-06-01 | — | — | US | disclosed |
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2017-06-01 | — | — | US | disclosed |
| US-9388192-B2 | Benzimidazole derivatives as Kinase Inhibitors | SELVITA S.A. (PL) | 2016-07-12 | — | — | US | disclosed |
| US-9388192-B2 | Benzimidazole derivatives as Kinase Inhibitors | SELVITA S.A. (PL) | 2016-07-12 | — | — | US | disclosed |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | Ryvu Therapeutics S.A. (PL) | 2015-11-26 | — | — | US | disclosed |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | Ryvu Therapeutics S.A. (PL) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174013-B2 | Benzimidazole derivatives as kinase inhibitors | PIM1, PIM3, PIM2 | KCNH2 2265/4885STK17B 140/4885STK17A 135/4885 |
| US-20170152249-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM3, PIM2 | KCNH2 2240/4885STK17B 121/4885STK17A 116/4885 |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | PIM1, PIM3, PIM2 | KCNH2 2240/4885STK17B 121/4885STK17A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.